PI3K inhibitor

DRUG2 trials

Sponsors

SecuraBio, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Chronic Lymphocytic LeukemiaFollicular LymphomaLymphomaLymphoma, Non-HodgkinLymphoma, Small LymphocyticLymphoma, T-CellNK-LGL LeukemiaT-LGL Leukemia

Phase 2

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

RecruitingNCT06530550

Institute of Hematology & Blood Diseases Hospital, ChinaLymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia

Start: 2024-08-10End: 2028-07-10Target: 51Updated: 2025-08-12

Unknown Phase

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

TerminatedNCT04342117

SecuraBioChronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoma +2

Start: 2020-04-23End: 2020-12-31Updated: 2021-03-17